NBC4: Rockville Biotech Shares Encouraging News in HIV Fight


CEO Jeff Galvin joins NBC 4 to discuss the success of AGT’s Phase 1 HIV gene and cell therapy clinical trial, as well as plans to advance to Phase 2 through Addimmune a new spinoff company harnessing gene and cell therapy technologies for a potential HIV cure. Addimmune will focus solely on HIV research while building upon more than a decade of work by American Gene Technologies®. Join us as we Imagine A World Without HIV℠!

Be Part of Our Mission to Make an Impact

Sign up for our newsletter and follow our journey to potentially eradicate HIV with our gene therapy.

Subscribe Here!


Scroll to Top